Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Bevacizumab and Chemotherapy in ALK-rearranged NSCLC (BEYOND)
NCT05266846Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- May 2024
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in lung adenocarcinoma (2 arms), sponsored by Hunan Cancer Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started May 2024; status: recruiting.
02
Drugs
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT05266846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05266846.